CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 25, 2018--
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its third quarter 2018 investor update conference call and webcast at
8:30 a.m. Eastern Time on Tuesday, November 6, 2018. Individuals
interested in participating in the call should dial (877) 643-7155(U.S.
and Canada) or (914) 495-8552 (international) using conference ID number
6878976. To access the webcast, please visit the Investors section of
Ironwood’s website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting November 6,
2018 at approximately 11:30 a.m. Eastern Time, running through 11:30
a.m. Eastern Time on November 13, 2018. To listen to the replay, dial
(855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 6878976. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
(Nasdaq: IRWD) is a commercial biotechnology company focused on creating
medicines that make a difference for patients, building value for our
fellow shareholders, and empowering our passionate team. We discovered,
developed and are commercializing linaclotide, the U.S. branded
prescription market leader for adults with irritable bowel syndrome with
constipation (IBS-C) or chronic idiopathic constipation (CIC). Our
pipeline priorities for linaclotide include a Phase IIIb trial
evaluating its efficacy and safety on multiple abdominal symptoms,
including abdominal bloating, pain, and discomfort in adult patients
with IBS-C, as well as research into a formulation of linaclotide
designed to relieve pain across all IBS subtypes.
We are also advancing a pipeline of innovative product candidates in
areas of significant unmet need, including persistent gastroesophageal
reflux disease, diabetic nephropathy, heart failure with preserved
ejection fraction and sickle cell disease. Ironwood was founded in 1998
and is headquartered in Cambridge, Mass. For more information, please
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181025006047/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Meredith Kaya, 617-374-5082
President, Investor Relations and Corporate Communications